Skip to main content

Table 2 Risk factors of GARFIELD-AF Dutch cohorts 1–3

From: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF)

Variable Statistics Cohort 1 retrospective patients
(n = 93)
Cohort 1 prospective patients
(n = 106)
Cohort 2
(n = 412)
Cohort 3
(n = 318)
Total without retrospective patients
(n = 836)
Diabetes, n (%) Yes 20 (21.5) 20 (18.9) 81 (19.7) 58 (18.2) 159 (19.0)
Smoking status, n (%) No 26 (41.3) 31 (37.8) 134 (45.0) 127 (51.8) 292 (46.7)
Ex-smoker 26 (41.3) 37 (45.1) 119 (39.9) 75 (30.6) 231 (37.0)
Current smoker 11 (17.5) 14 (17.1) 45 (15.1) 43 (17.6) 102 (16.3)
Unknown 30 24 114 73 211
CHA2DS2-VASc score n (missing) 87 (6) 103 (3) 388 (24) 302 (16) 793 (43)
Mean (SD) 3.0 (1.3) 3.1 (1.5) 3.1 (1.5) 3.0 (1.5) 3.0 (1.5)
HAS-BLED score n (missing) 48 (45) 59 (47) 194 (218) 161 (157) 414 (422)
Mean (SD) 1.2 (0.9) 1.4 (1.0) 1.3 (0.9) 1.3 (0.9) 1.3 (0.9)
  1. Data from the first three GARFIELD-AF prospective cohorts – cohort 1: Dec 2009–Oct 2011; cohort 2: Oct 2011–Jun 2013; cohort 3: Jun 2013–Jun 2014